Effect of Chronic Levodopa, Bromocriptine and SKF-38393 on Dyskinesia and Dopamine Receptors in MPTP-parkinsonian Monkeys
The existence of two brain dopamine (DA) receptor subtypes (D-1 and D-2) has now gained widespread acceptance. More recently, it has been reported that D-1 and D-2 receptors in normosensitive striatum are functionally linked (Barone et al., 1986). The use of the D-2 selective agonist, bromocriptine, in previously untreated parkinsonian patients has been reported to induce little or no dyskinesia (Lees and Stern, 1981). The interaction between D-1 and D-2 receptors in treatment of Parkinson’s disease may therefore be important particularly for the induction of dyskinesia observed after therapy with L-DOPA, a mixed DA agonist.
KeywordsDopamine Receptor Nucleus Accumbens Parkinsonian Symptom Brain Dopamine Chronic Levodopa
Unable to display preview. Download preview PDF.